Michael J. Morris, MD, medical oncologist, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the use of PET imaging for patients with prostate cancer.
More on prostate cancer: onclive.com/specialty/prostate-cancer
- Dr. Morris Discusses Bone Metastases and PET Imaging in Prostate Cancer ( Download)
- Dr. Morris on the Promise of PSMA-Targeted PET Imaging in Prostate Cancer ( Download)
- Dr. Morris on Deciding Among PET Tracers in Prostate Cancer ( Download)
- Dr. Morris on Next Steps for PSMA–Targeted PET Imaging in Prostate Cancer ( Download)
- Dr. Den Discusses Bone Metastases in Prostate Cancer ( Download)
- Dr. Morris on the Next Steps with Bone Biomarkers for Prostate Cancer ( Download)
- Evaluating Tumor-Directed PET Imaging of mCRPC Bone Metastases Using Zr-89-J591 ( Download)
- Imaging of Metastatic Prostate Cancer: Whole Body MRI and Novel PET Techniques ( Download)
- Michael Morris, MD Discusses the Future of PSMA-Targeted Therapies in APC - Part 1 ( Download)
- Dr. Morris of Impact of PSMA-Targeted Imaging on Clinical Management of Prostate Cancer ( Download)
- Dr. Morris on Mechanism of Action for Radium-223 ( Download)
- Dr. Desai on MRI Imaging for Bone Metastases in CRPC ( Download)
- Dr. Morris on Biomarkers in Prostate Cancer Trials ( Download)
- Prostate Cancer Osteoblastic Bone Metastases ( Download)
- Michael Morris, MD Discusses the Future of PSMA-Targeted Therapies in APC - Part 2 ( Download)
